clinical trial · NCT06343064
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Avistone Biotechnology Co., Ltd.·phase2·recruiting·n = 156
Non-Small-Cell Lung CancerVebreltinibPLB1004
brief summary
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
started
Jun 13, 2023
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
May 21, 2025
detailed description
Open label, multicenter Phase Ib/II clinical study to evaluate the safety, efficacy, and pharmacokinetics of Vebreltinib in combination with PLB1004 in patients with locally advanced or metastatic non-small cell lung cancer with MET overexpression or MET amplification following EGFR-TKI treatment failure.
official title
A Phase Ib/II Study of Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol